In this interview with The Dales Report, InMed CEO Eric A. Adams talks about how the scalability of synthesized rare cannabinoids will make them more affordable.
Read the article and watch the full video at The Dales Report.
In this interview with The Dales Report, InMed CEO Eric A. Adams talks about how the scalability of synthesized rare cannabinoids will make them more affordable.
Read the article and watch the full video at The Dales Report.
At the 12th World Congress on Itch (WCI), held in Miami on November 5-7, 2023, InMed’s Senior VP, Clinical and Regulatory Affairs, Alexandra Mancini presented
InMed’s INM-901 is a drug candidate being developed as a potential treatment for Alzheimer’s disease. Promising early studies demonstrate INM-901’s neuroprotective effects and an ability
Jerry Griffin, VP of Sales and Marketing at BayMedica, InMed’s subsidiary, joins this live panel discussion “Transforming the CPG Landscape: Why Rare Cannabinoids Ingredients are
© Copyright 2024 InMed Pharmaceuticals Inc.
"*" indicates required fields